GSKs 2.5bn Cough Drug Collapse|-3.2% as 2031 Revenue Bridge Cracks

A £2bn Deal, a Flat Line, and a Share Price Drop

GSK fell 3.2% to 1,892.75p on Friday after the British pharmaceutical giant announced it was discontinuing development of camlipixant, the chronic cough drug it acquired when it bought Bellus Health for approximately $2 billion in 2023. The CALM-1 and CALM-2 Phase 3 trials had returned what the company described as 'limited efficacy unlikely to transform patient care' — a phrase that effectively closed the programme.

The data told a contradictory story. In CALM-1, the 50mg twice-daily dose did achieve a statistically significant reduction in 24-hour cough frequency versus placebo at week 12 — the primary endpoint was met. Yet in CALM-2, run predominantly in China, the same dose failed to replicate that result at 24 weeks. The lower 25mg dose showed no significant improvement in either study, and key secondary endpoints including patient-reported outcomes missed their thresholds in both trials. One trial said yes, one said no, and the lower dose said nothing at all.

Here is the question that neither the share price movement nor the analyst note fully resolves. Jefferies analyst Michael Leuchten called the failure 'disappointing' but said it is 'not a material setback to the GSK equity story,' pointing to the company's strengthening oncology portfolio. Yet GSK's own prior disclosures described camlipixant as a crucial element in its plan to reach more than £40 billion in annual revenues by 2031 — a plan that treated £2.5 billion in peak camlipixant sales as a load-bearing pillar. The analyst's reassurance and the company's own arithmetic do not sit easily together, and the bottleneck is the oncology portfolio's current trajectory relative to the gap that just opened.

What the £2.5bn Was Supposed to Build

GSK paid approximately $2 billion to acquire Bellus Health in June 2023. The strategic logic was explicit: camlipixant was the main asset driving that acquisition, and the drug was assigned a peak-sales potential of £2.5 billion, with the refractory chronic cough indication alone described by Jefferies as a potential $1 billion opportunity. That ceiling has now been removed from the company's revenue model entirely. The £40 billion 2031 revenue target was built with camlipixant as a contributor — and the programme that justified the $2 billion outlay has been discontinued after three years of Phase 3 development.

Jefferies' manageable verdict rests on a buried assumption: that the oncology portfolio had already grown large enough to absorb camlipixant's absence before today's data arrived. This is not obviously true. Jemperli, GSK's PD-1 inhibitor, recorded sales growth of 40% in the first quarter of this year, reaching £232 million — a strong run-rate, but still a fraction of the £2.5 billion ceiling camlipixant was supposed to add. The oncology replacement thesis requires not just that Jemperli is growing, but that it can grow fast enough, and across enough new indications, to close a gap measured in billions rather than hundreds of millions. That trajectory is not confirmed in today's data — it is a forward bet, and one the current rate of growth has not yet validated.

There is a deeper question about the capital allocation decision itself. Camlipixant is a P2X3 receptor antagonist, and it has now joined Bayer's eliapixant, Shionogi's sivopixant, and Merck's gefapixant in a class that has consistently failed or underperformed in refractory chronic cough. GSK acquired Bellus after camlipixant had already failed one Phase 2 trial; a second mid-stage study delivered stronger results, and the company paid $2 billion on that revised reading. The class's failure rate was visible when the deal was signed. The question of whether the current management team — CEO Luke Miels and R&D chief Tony Wood — adequately weighted that history is not absolved by Jefferies' portfolio reassurance, and Leuchten himself noted that they 'would have been involved here.'

Jemperli and the Verification Gap

The counter-thesis begins with Jemperli. GSK's PD-1 inhibitor has been gaining momentum as a genuine oncology growth driver, with sales up 40% to £232 million in the first quarter of this year. The AZUR-1 Phase 2 trial in dMMR/MSI-H locally advanced rectal cancer met its primary endpoint at 12 months, showing a meaningful and sustained clinical complete response rate that positions Jemperli as potentially allowing some patients to avoid surgery, radiotherapy and chemotherapy altogether. GSK has said it intends to file with regulators including under the FDA's accelerated approval pathway, and has Breakthrough Therapy Designation for this indication.

But the verification gap is real. GSK has set a £2 billion-plus peak-sales target for Jemperli, with roughly half expected from endometrial cancer — where the drug is already approved with chemotherapy — and the remainder from colorectal and head-and-neck cancer indications that have not yet been filed. The rectal cancer AZUR-1 data are interim Phase 2 results, not a completed Phase 3; the AZUR-2 randomised Phase 3 trial in resectable colon cancer is still running. Even a successful path through regulators takes years. The question is whether Jemperli's oncology momentum can grow from £232 million in quarterly sales to a level that compensates for camlipixant's removal before the 2031 target window closes.

There is one remaining optionality from the Bellus acquisition. GSK is continuing the Phase 2b BALANCE trial evaluating camlipixant in irritable bowel syndrome — both the diarrhoea-predominant and mixed-bowel-habits variants — with completion expected in March 2027. If that readout is positive, some portion of the original investment thesis survives. If it fails, the entire Bellus rationale will have been consumed by two therapeutic areas that did not deliver. The BALANCE result is the earliest specific checkpoint that still connects to the camlipixant revenue story; it does not approach the scale of the RCC opportunity, but it is the first binary confirmation the market will receive on whether any residual value exists in the original deal.

Entry Setup or Capital Allocation Trap

Today's 3.2% decline prices in the loss of one drug programme, but it does not yet price in a verdict on the £40 billion 2031 revenue target. That is the reframe the share price decline obscures: the real question is not whether camlipixant mattered in isolation, but whether its absence opens a gap in the long-range revenue bridge that oncology cannot fill at its current trajectory. Jefferies says it does not. GSK's own prior arithmetic suggested it did.

For holders, the monitoring variable is Jemperli's regulatory progress — specifically, the AZUR-2 Phase 3 readout in colorectal cancer and any update on the AZUR-1 accelerated approval filing timeline. If Jemperli secures a colorectal approval and the quarterly sales run-rate continues above 40% growth, the oncology replacement thesis gains real traction. If the approvals slip or growth decelerates, the gap left by camlipixant becomes harder to close before 2031. For watchers, the nearest binary checkpoint is the BALANCE trial in March 2027 — a positive IBS readout would preserve some residual Bellus value; a failure would confirm that the $2 billion acquisition yielded nothing of lasting worth, and that management's capital allocation judgement on a class with a visible failure record remains unresolved.

The position becomes an entry setup if Jemperli's Phase 3 data arrive on schedule and positive, confirming that oncology's trajectory already compensates for what camlipixant was supposed to contribute — in that case, today's 3.2% decline is the mispricing. The position becomes a trap if AZUR-2 readouts are delayed or negative while BALANCE also misses in March 2027, leaving the £40 billion 2031 target exposed on two fronts: the bridge asset gone and the replacement drug stalled. Neither outcome is decided today; the distinction between the two is exactly what a £2bn acquisition and a failed Phase 3 class have left unresolved.